Article Text

other Versions

Download PDFPDF
Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy : comparison of the presence of serous retinal pigment epithelial detachment
  1. Masaaki Saito (smasaaki{at}fmu.ac.jp),
  2. Tomohiro Iida (iidat{at}fmu.ac.jp),
  3. Dai Nagayama (dai-n{at}fmu.ac.jp)
  1. Department of Ophthalmology, Fukushima Medical University School of Medicine, Japan
  2. Department of Ophthalmology, Fukushima Medical University School of Medicine, Japan
  3. Department of Ophthalmology, Fukushima Medical University School of Medicine, Japan

    Abstract

    Aim: To evaluate outcomes after photodynamic therapy (PDT) with verteporfin in Japanese patients with age-related macular degeneration (AMD) or polypoidal choroidal vasculopathy (PCV) and compare results with the presence/absence of a retinal pigment epithelial detachment (PED).

    Methods: We retrospectively reviewed 183 eyes with subfoveal choroidal neovascularization secondary to AMD with more than 3 months follow-up (range, 3-36; mean, 15.6). A serous PED developed in 44 of 183 eyes.

    Results: A total of 124 eyes (67.8%) completed 12 months follow-up. In 49 eyes with typical AMD, the best-corrected visual acuity (BCVA) improved a mean of 0.48 line. A significant (p<0.05 to p<0.0005) decline in VA occurred in eyes with a serous PED during any 3-month period. In 75 eyes with PCV, the BCVA at 12 months improved a mean of 1.79 lines. There was no significant difference between the BCVA in 22 eyes with a PED and 53 eyes without a PED during any 3 months.

    Conclusions: In eyes with typical AMD, a serous PED was associated with a significant decline in BCVA compared with eyes without a serous PED. In eyes with PCV, the visual outcomes were unaffected by a serous PED. When PDT is administered, differentiating PCV from typical AMD using indocyanine green angiography is important.

    Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.